NASDAQ:OKUR OnKure Therapeutics Q2 2025 Earnings Report $2.94 -0.16 (-5.16%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$2.95 +0.01 (+0.34%) As of 05:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast OnKure Therapeutics EPS ResultsActual EPS-$1.14Consensus EPS -$1.23Beat/MissBeat by +$0.09One Year Ago EPSN/AOnKure Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOnKure Therapeutics Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsOnKure Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile OnKure Therapeutics Earnings HeadlinesOnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare ConferenceAugust 31, 2026 | globenewswire.comOnKure Therapeutics Inc. - Ordinary Shares - Class AAugust 19, 2026 | money.usnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)August 6, 2026 | theglobeandmail.comOnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsAugust 4, 2026 | globenewswire.comOnKure Therapeutics Stock Short Interest Report | NASDAQ:OKUR | BenzingaJuly 14, 2026 | benzinga.comSee More OnKure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email. Email Address About OnKure TherapeuticsOnKure Therapeutics (NASDAQ:OKUR) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company is working to discover and advance small-molecule therapies designed to target biological pathways involved in tumor growth and the suppression of antitumor immune responses. Its lead investigational product candidate, OKN4395, is an orally administered small-molecule antagonist of the EP4 receptor, which is associated with tumor-promoting inflammation and immune suppression. OnKure is evaluating OKN4395 as a potential treatment for advanced solid tumors, including in combination with immune checkpoint inhibitors. The company’s programs are being developed for patients with cancers that may benefit from targeted approaches to the tumor microenvironment. OnKure Therapeutics is headquartered in Boulder, Colorado, and its development activities are focused on advancing oncology candidates through clinical testing and potential regulatory approval. As with other clinical-stage biotechnology companies, its product candidates remain investigational and are subject to the results of clinical trials and regulatory review.View OnKure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
